SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively trending as market participants analyze former President Trump's speech at the World Economic Forum in Davos. His remarks, particularly those concerning Greenland and the broader economic outlook, are sparking intense debate within the community. Discussion centers on whether his bullish pronouncements or controversial international rhetoric will ultimately dictate market sentiment amid geopolitical tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's special address at the World Economic Forum is generating intense discussion around DJT, with market participants keenly focused on his comments regarding tariffs and the proposed acquisition of Greenland. The community is actively debating the potential for global economic repercussions, as some express concern about market instability and a 'Sell America' trade, while others praise his disruptive approach to international policy.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after an earnings report that, despite exceeding estimates, has sparked significant debate regarding subscriber growth, cautious guidance, and the strategic implications of its potential Warner Bros. Discovery acquisition. While many view the current dip as an oversold buying opportunity for a market leader, concerns around debt, a paused buyback program, and slower growth are driving a bearish outlook, with the community sharply divided on the stock's immediate future.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently a top trending stock after its subsidiary, Lucid Diagnostics, announced a major contract with the U.S. Department of Veterans Affairs for its EsoGuard esophageal DNA test. This significant development has ignited investor excitement, with many discussing the potential for substantial price movement given the company's low float, even as some longer-term holders express caution regarding historical performance.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid an intense geopolitical spotlight on Greenland's strategic rare earth minerals, fueled by recent statements from a former President emphasizing the territory's importance for national security. The community is actively discussing significant price volatility and potential market manipulation, with many anticipating a major business update from the company as a key catalyst. This narrative positions CRML as a central player in securing a Western critical minerals supply chain, driving strong bullish sentiment among investors despite recent fluctuations.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing intense community discussion, fueled by recent high-grade silver drill results and a broadly bullish sentiment across precious metals markets. Investors are actively debating the company's valuation, weighing its significant resource potential and strategic investor interest against its current pre-production status and capital requirements.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to widespread market discussion around geopolitical tensions, specifically former President Trump's rhetoric on Greenland and trade policy during his Davos address. The community is actively debating whether perceived softening in his stance will alleviate pressure or if broader concerns over trade relations and central bank policy will continue to influence growth-oriented tech assets.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is trending following a significant AI licensing partnership in Africa, which includes an AI-driven student wellbeing pilot at Nelson Mandela University, alongside ongoing discussions about AI solutions for pharma. The community is actively discussing the stock's potential for a short squeeze, citing a tightly held float and high borrow fees that are fueling intense trading volatility. This interest is further buoyed by the company's regained Nasdaq compliance and its expanding presence in the AI sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community reacts to its announced plans for a new rare earth metals and alloys production facility in France, securing substantial government backing. This development is seen as a pivotal step in establishing independent rare earth supply chains, aligning with growing geopolitical emphasis on national security and domestic sourcing away from China. Investors are actively discussing USAR's role in supplying critical materials for electric vehicles, defense, and advanced technology.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

Aqua Metals is trending after announcing a multi-year supply agreement with 6K Energy, reinforcing its position in domestic battery material commercialization. This news has sparked significant bullish momentum and speculation around its low float; however, a vocal segment of the community expresses skepticism, citing the company's history of frequent stock dilution and reverse splits. The broader conversation reflects ongoing interest in critical mineral recycling and securing US supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio generated increased retail chatter on Monday after the company said that the FDA had awarded Orphan Drug Designation to its experimental CAR-T drug MB-101 for the treatment of astrocytomas and glioblastoma (GBM), two types of fast-growing brain tumors.The treatment, which targets the IL13Ra2 protein, is currently being studied in a Phase 1 trial.&nbsp;In early results published in Nature Medicine, MB-101 was well-tolerated, with 50% of patients seeing stable disease or better.&nbsp;Among them, two had partial responses, and two others achieved complete responses lasting 7.5 months and more than five and a half years.Mustang is also looking at a combo approach, pairing MB-101 with MB-108, an HSV-1-based oncolytic virus, in a regimen it calls MB-109.&nbsp;Preclinical studies suggest that MB-108 may help modify the tumor microenvironment, essentially turning "cold" tumors into "hot" ones to improve efficiency of MB-101 CAR-T cells.MB-108 already has Orphan Drug status for malignant glioma, and Mustang says the combination could allow MB-101 to move more effectively through the tumor, activate in the right spots, and target cancer cells more precisely.Both MB-101 and MB-108 are still enrolling patients in Phase 1 studies, including one at City of Hope, the other at The University of Alabama at Birmingham.&nbsp;However, moving the MB-109 program forward will depend on whether the company can secure more funding or land a partnership deal.Orphan Drug status gives MB-101 access to several FDA benefits, including seven years of market exclusivity if approved, tax breaks on clinical trial costs, and waived fees, which are all part of a program designed to support treatments for rare conditions affecting fewer than 200,000 people in the U.S.On Stocktwits, retail sentiment for Mustang Bio was ‘extremely bullish’ amid a 105,200% surge in 24-hour message volume.One user on Stocktwits suggested that shares of $MBIO could climb to the $15–$20 range if the company secures a partnership, noting the stock “has life” and is poised to grow, especially for those who bought in below $1.20.<stembedurl>https://stocktwits.com/Invest2live/message/620129007</stembedurl>Another user speculated that a partnership or buyout by a larger pharmaceutical company could be in play, calling the day’s FDA designation “great news” for&nbsp;<a href="https://stocktwits.com/symbol/MBIO">Mustang Bio</a>.<stembedurl>https://stocktwits.com/BostonBigBoyisBack/message/620124257</stembedurl>The stock has declined 68% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug

The company is advancing a novel combination of its CAR-T drug MB-101 and oncolytic virus MB-108, with both treatments currently enrolling patients in Phase 1 trials. 

Equity

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Mustang Bio Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '24	-$0.14	-$17.50	-12400.00%	MISSED
Q1 '24	-$0.46	--	--	N/A

MBIO
Mustang Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '24

Historical Earnings

Latest MBIO News

MBIOMustang Bio Inc